Indoco Remedies Ltd. (NSE: INDOCO, BSE: 532612) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹2,267 Cr, it ranks #1,184 by market cap among the 6,137 Indian listed companies on FinBizNet, and #37 of 86 in Medicinal Chemicals and Botanical Products. At ₹226.50 (as of 25 Oct 2026), the share price is 21.4% below its 52-week high of ₹288.00 and 39.7% above its 52-week low of ₹162.19. The share price is down 22.5% over one year and down 7.0% over three months.
| Current Price | ₹226.50 |
|---|---|
| Market Cap | ₹2,267 Cr |
| NSE Symbol | INDOCO |
| BSE Code | 532612 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | -22.9 |
| Return on Equity | -10.12% |
| Return on Assets | 0.40% |
| 52-Week Range | ₹162.19 – ₹288.00 |
| 1-Year Price Change | -22.5% |
| 3-Month Price Change | -7.0% |
| Beta (1Y) | 0.36 |
| Dividend Yield | 0.08% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.indoco.com |
| Revenue | ₹468 Cr |
|---|---|
| Net Profit | ₹65 Cr |
| Net Margin | 14.0% |
| EPS (Basic) | ₹7.09 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and valid
1. Pharmaceuticals-This segment manufactures and sells formulations and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Indoco Remedies Ltd. | ₹2,267 Cr | -22.9 | -10.12% | ₹468 Cr | -22.5% |
Listed by market capitalisation. Ratios are shown for context only.
Indoco Remedies Ltd. is trading at ₹226.50, with a market capitalisation of ₹2,267 Cr.
Indoco Remedies Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Indoco Remedies Ltd. has a P/E of -22.9 and a return on equity of -10.12%.
Indoco Remedies Ltd. is listed on the NSE under the symbol INDOCO and on the BSE under the scrip code 532612.
Indoco Remedies Ltd.'s share price is down 22.5% over one year and down 7.0% over three months. Its 52-week range is ₹162.19 to ₹288.00.
In Q1 FY27, Indoco Remedies Ltd. reported revenue of ₹468 Cr and net profit of ₹65 Cr, with basic EPS of ₹7.09 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.